T 0376/15 (Triple therapy for diabetes type 2/SANOFI) of 08.10.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:T037615.20181008
- Date of decision
- 8 October 2018
- Case number
- T 0376/15
- Online on
- 31 January 2019
- Petition for review of
- -
- Application number
- 09175877.1
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
- Applicant name
- Sanofi-Aventis Deutschland GmbH
- Opponent name
- Generics [UK] Limited
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83
- Keywords
- Main request:
Novelty - (yes)
Inventive step - (yes)
Sufficiency of disclosure - (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division with the order to maintain the patent as amended in the following version:
Description: pages 1-7 of the patent specification;
Claims: 1-11 of the main request, received during the oral proceedings on 8 October 2018.